U.S. Department of Health and Human Services
Clinical Trials Search Results
Search results 1 - 10 of 13 for FDA-Approved HIV Drugs, Odefsey
Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV
Condition: Hiv
NCT ID: NCT03451032- Red stop iconCompleted
- Email this trial
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Condition: HIV-1 Infection
NCT ID: NCT02345252- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
Condition: HIV-1 Infection
NCT ID: NCT02345226- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Condition: HIV-1 Infection; HCV Infection
NCT ID: NCT02707601- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy
Condition: HIV
NCT ID: NCT02800655- Green tick iconRecruiting
- Email this trial
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Condition: Human Immunodeficiency Virus; Hepatitis C, Chronic
NCT ID: NCT02660905- Question Mark iconUnknown status
- Email this trial
Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
NCT ID: NCT02016924- Green tick iconRecruiting
- Email this trial
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Condition: HIV-1 Infection
NCT ID: NCT03631732- Red stop iconActive, not recruiting
- Email this trial
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
Condition: HIV-1 Infection
NCT ID: NCT02605954- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
Condition: HIV-1 Infection
NCT ID: NCT02616783- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Email Updates
